The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
DU‐145 and PC‐3 human prostate cancer cell lines express androgen receptor: Implications for the androgen receptor functions and regulation
Abstract
The majority of human prostate cancer cell lines, including the two “classical” cell lines DU‐145 and PC‐3, are reported to be androgen receptor (AR)‐negative. However, other studies have provided evidence that the DU‐145 and PC‐3 cell lines express AR mRNA. These contradictory observations prompted us to investigate whether DU‐145 and PC‐3 cell lines express the androgen receptor. Using antipeptide antibodies directed against three distinct regions of the human AR protein and an improved method to detect AR protein in immunoblotting, we report that DU‐145 and PC‐3 cell lines express AR protein. We found that the relative levels of the AR mRNA and protein that were detected in DU‐145 and PC‐3 cell lines were lower than the LNCaP, an AR‐positive cell line. Moreover, the antibody directed against the non‐variant region (amino acids 299–315), but not the variant N‐ or C‐terminal region (amino acids 1–20 and 900–919, respectively) of the human AR protein, detected the expression of AR in all prostate cancer cell lines. Notably, treatment of these cell lines with dihydrotestosterone (DHT) resulted in measurable increases in the AR protein levels and considerable nuclear accumulation. Although, treatment of DU‐145 and PC‐3 cells with DHT did not result in stimulation of the activity of an AR‐responsive reporter, knockdown of AR expression in PC‐3 cells resulted in decreases in p21 CIP1 protein levels, and a measurable decrease in the activity of the p21‐luc‐reporter. Our observations demonstrate the expression of AR protein in DU‐145 and PC‐3 prostate cancer cell lines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Androgen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942
Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938
Molecular genetics of prostate cancer
Abate-Shen, C., & Shen, M. M. (2000) · Genes & Development · doi:10.1101/gad.819500 · Cited by 735
Molecular characterization of human prostate carcinoma cell lines
van Bokhoven, A., Varella‐Garcia, M., Korch, C., Johannes, W. U., Smith, E. E., Miller, H. L., Nordeen, S. K., Miller, G. J., & Lucia, M. S. (2003) · The Prostate · doi:10.1002/pros.10290 · Cited by 633
Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G. C., Klocker, H., & Čulig, Z. (1998) · PubMed · Cited by 437
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer
Gnanapragasam, V. J., Leung, H. Y., Pulimood, A. S., Neal, D. E., & Robson, C. N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2179 · Cited by 189
Lu, S., Liu, M., Epner, D. E., Tsai, M., & Tsai, M. (1999) · Molecular Endocrinology · doi:10.1210/me.13.3.376 · Cited by 185
Cited by
Chen, Y.-Y., Wu, H.-C., Sun, J.-S., Dong, G.-C., & Wang, T.-W. (2013) · Langmuir · doi:10.1021/la400268p · Cited by 126
SILAC-based quantitative MS approach reveals Withaferin A regulated proteins in prostate cancer
Kumar, R., Nayak, D., & Somasekharan, S. P. (2021) · Journal of Proteomics · doi:10.1016/j.jprot.2021.104334 · Cited by 19
Metadata
- Authors
- Alimirah, F., Chen, J., Basrawala, Z., Xin, H., & Choubey, D.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2006-03-24
- Volume
- 580
- Issue
- 9
- Pages
- 2294-2300
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2025312106
- Cited by
- 265
- References
- 26
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.